Pacific Biosciences of California (NASDAQ:PACB) is scheduled to announce its earnings results after the market closes on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). Pacific Biosciences of California had a negative return on equity of 95.29% and a negative net margin of 100.09%. The business had revenue of $21.58 million for the quarter, compared to analysts’ expectations of $24.45 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
PACB stock opened at $4.08 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.28 and a current ratio of 4.33. Pacific Biosciences of California has a 1-year low of $2.02 and a 1-year high of $5.82. The firm has a market capitalization of $539.64 million, a price-to-earnings ratio of -4.69 and a beta of 2.13.
Several research analysts have weighed in on PACB shares. Cantor Fitzgerald set a $8.00 price objective on Pacific Biosciences of California and gave the stock a “buy” rating in a research report on Thursday, October 11th. Zacks Investment Research raised Pacific Biosciences of California from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research report on Tuesday, July 24th. BidaskClub cut Pacific Biosciences of California from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 18th. Piper Jaffray Companies reissued a “hold” rating and issued a $3.80 price objective on shares of Pacific Biosciences of California in a research report on Friday, August 3rd. Finally, Cowen started coverage on Pacific Biosciences of California in a research report on Friday, October 19th. They issued an “outperform” rating and a $6.50 price objective on the stock. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.31.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
Featured Article: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.